


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-34 (Canceled).

35. (Currently Amended) A chemical compound of formula (I):



wherein:

R<sub>1</sub> to R<sub>3</sub> are independently selected from hydrogen and lower alkyl;

X<sub>1</sub> is selected from N and C-R<sub>4</sub>;

X<sub>2</sub> is selected from N and C-R<sub>5</sub>;

X<sub>3</sub> is selected from N and C-R<sub>6</sub>;

X<sub>4</sub> is selected from N and C-R<sub>7</sub>;

wherein only one of X<sub>1</sub> to X<sub>4</sub> is N;

R<sub>4</sub>, R<sub>5</sub> and R<sub>7</sub> are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkoyl, aryloyl, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, dialkylamino, nitro, cyano, carboalkoxy, carboaryloxy and carboxy; and

R<sub>6</sub> is selected from hydrogen, halogen, alkyl, aryl, aryloxy, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, dialkylamino and cyano;

with the proviso that R<sub>4</sub> to R<sub>7</sub> are not all selected as hydrogen,

or a pharmaceutically acceptable salt[[,]] or addition compound ~~or prodrug~~ thereof.

36. (Previously Presented) A compound according to claim 35, wherein R<sub>1</sub> is selected from hydrogen and methyl.

37. (Previously Presented) A compound according to claim 35, wherein R<sub>2</sub> is hydrogen.

38. (Previously Presented) A compound according to claim 35, wherein R<sub>3</sub> is selected from hydrogen and methyl.

39. (Previously Presented) A compound according to claim 35, wherein X<sub>2</sub> is C-R<sub>5</sub>.

40. (Previously Presented) A compound according to claim 35, wherein X<sub>3</sub> is C-R<sub>6</sub>.

41. (Previously Presented) A compound according to claim 35, wherein X<sub>4</sub> is C-R<sub>7</sub>.

42. (Previously Presented) A compound according to claim 35, wherein X<sub>1</sub> is C-R<sub>4</sub>.

43. (Previously Presented) A compound according to claim 35, wherein two of R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are hydrogen.

44. (Previously Presented) A compound according to claim 43, wherein R<sub>4</sub> and R<sub>6</sub> are hydrogen.

45. (Previously Presented) A compound according to claim 35, wherein two of R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are independently selected from hydrogen, chlorine, fluorine, trifluoromethyl and bromine.

46. (Previously Presented) A compound according to claim 35, wherein three of R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are hydrogen.

47. (Previously Presented) A compound according to claim 46, wherein R<sub>4</sub>, R<sub>6</sub> and R<sub>7</sub> are hydrogen.

48. (Previously Presented) A compound according to claim 35, wherein R<sub>4</sub> is hydrogen.

49. (Previously Presented) A compound according to claim 35, wherein R<sub>5</sub> is halogen.

50. (Previously Presented) A compound according to claim 35, wherein R<sub>6</sub> is hydrogen.

51. (Previously Presented) A compound according to claim 35, wherein R<sub>7</sub> is halogen.

52. (Previously Presented) A compound according to claim 35, wherein the compound is:

(RS) 7-Chloro-1,2,3,4,10,10a-hexahydro-6-aza-pyrazino[1,2-a]indole furmarate.

53. (Previously Presented) A method of treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea comprising administering to a patient in need of such treatment an effective dose of a compound of formula (I) as set out in claim 35.

54. (Previously Presented) A method according to claim 53, wherein the disorders of the central nervous system are selected from depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioural disorders, behavioural disorders associated with dementia,

organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

55. (Previously Presented) A method according to claim 53, wherein the damage to the central nervous system is by trauma, stroke, neurodegenerative diseases or toxic or infective CNS diseases.

56. (Previously Presented) A method according to claim 55, wherein said toxic or infective CNS disease is encephalitis or meningitis.

57. (Previously Presented) A method according to claim 53, wherein the cardiovascular disorder is thrombosis.

58. (Previously Presented) A method according to claim 53, wherein the gastrointestinal disorder is dysfunction of gastrointestinal motility.


59. (Previously Presented) A method according to claim 53, wherein said disorder is obesity.

60. (Previously Presented) A pharmaceutical composition comprising a compound of formula (I) as set out in claim 35 in combination with a pharmaceutically acceptable carrier or excipient.

61. (Previously Presented) A method of making a pharmaceutical composition comprising combining a compound of formula (I) as set out in claim 35 with a pharmaceutically acceptable carrier or excipient.

62. (Previously Presented) A process for the preparation of a compound of formula (I) according to claim 35, said process comprising the steps of:

(i) treating a compound of formula (IX) with an aldehyde of formula  $RCHO$  and then exposing the compound to acid to obtain a compound of formula (X), wherein  $X_1$ ,  $X_2$ ,  $X_3$ ,  $X_4$ ,  $R_2$  and  $R_3$  are as described in claim 35, and



(ii) reduction of a compound of formula (X).